Bilirubin estimation in amniotic fluid obtained by amniocentesis is effective in predicting the severity of hemolytic disease of the newborn (HDN), as it gives the best indication of the degree of intrauterine hemolysis. It can be used to predict fetal survival and can aid in making management decisions for affected infants.

To read more or access our algorithms and calculators, please log in or register.